olfactory receptor family 51 subfamily P member 1 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR51P1P profile across patient tissues and cancer cell-line models. OR51P1P expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, OR51P1P is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, OR51P1P RNA expression shows 6,004 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and PRAD as cancer lineages where OR51P1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR51P1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR51P1P survival associations across molecular data types. OR51P1P RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR51P1P RNA expression–survival associations across cancer types. High OR51P1P expression shows unfavorable associations in STAD, DLBC, SARC, LUAD, CESC and SKCM. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for OR51P1P RNA expression.
This table summarizes OR51P1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR51P1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR51P1P shows higher tumor expression in PRAD. The PRAD box plot shows higher OR51P1P RNA expression in tumor versus normal tissue (log2 FC = +0.027, t-test p < 0.001).
This table shows molecular features associated with OR51P1P in patient tissues and cancer cell lines. In patient samples, OR51P1P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
